Intrinsiqq
Sellas Life Sciences Group Inc. logo

Sellas Life Sciences Group Inc. Dividend Analysis

SLS

⊜ Compare
Dividend0
No active dividend

This company discontinued its dividend after 2018.

Based on TTM and annual data · Not a buy/sell signal

This company does not pay dividends

Last dividend was paid in 2018. The company has not paid dividends in the last 7 years.

Does Sellas Life Sciences Group (SLS) pay a dividend?

Sellas Life Sciences Group (SLS) stopped paying a dividend after 2018 and pays nothing today. Free cash flow is currently negative, so there is no surplus to distribute. All figures are computed from company filings; this is analysis, not investment advice.

Frequently asked

Does Sellas Life Sciences Group (SLS) pay a dividend?+

No. Sellas Life Sciences Group (SLS) does not currently pay a dividend. The last payment in our data was in 2018, and nothing has been paid since.

How does Sellas Life Sciences Group return cash to shareholders?+

It largely does not. Sellas Life Sciences Group pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.

Could Sellas Life Sciences Group afford to pay a dividend?+

Not currently. Sellas Life Sciences Group's free cash flow is negative at -$28 million, meaning the business consumed cash over the period rather than generating it. A company funding a dividend from cash it is not producing would be paying shareholders out of its balance sheet or borrowings, which is not sustainable.

Which healthcare companies do pay dividends?+

Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Sellas Life Sciences Group.

SourceDividend analysis computed from the 10-Q filed 10 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Aug 2026. How this is calculated.

Fiscal year ends Dec. Earnings payout = dividends / net income. FCF payout = dividends / FCF. Yield = TTM DPS / price.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SLS

CompareIntrinsic value
MREOMereo BioPharma Group plc
$0.29-3.97%10
COYACoya Therapeutics Inc.
$3.61-9.30%10
PRLDPrelude Therapeutics Incorporated
$3.88-5.37%40
PLRXPliant Therapeutics Inc.
$0.86-0.13%10
AARDAardvark Therapeutics, Inc.
$1.36-5.56%10
ORMPOramed Pharmaceuticals Inc.
$4.11-2.84%35
NTHINeonC Technologies Holdings
$3.26+4.49%10
SLNSilence Therapeutics plc
$19.75-0.25%10

Held by ETFs

SLS is in 33 US ETFs. The largest of them, with SLS's weight in each:

Spot a number that looks wrong? Check it in SLS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SLS

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.